Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Opioid Induced Constipation Drugs Market

Opioid Induced Constipation Drugs Market Size

  • Report ID: GMI8483
  • Published Date: Mar 2024
  • Report Format: PDF

Opioid Induced Constipation Drugs Market Size

Opioid Induced Constipation Drugs Market was valued at around USD 2.1 billion in 2023 and is expected to grow at 4.8% CAGR during 2024 to 2032, driven by the increasing use of opioids coupled with the rising prevalence of gastrointestinal disorders.

 

The increasing use of opioids has become a pervasive healthcare concern, with a rising number of patients relying on these potent pain relievers for various medical conditions. However, alongside the benefits of opioid medications, there is a growing recognition of their adverse effects, particularly opioid-induced constipation (OIC), requiring the use of drugs for the treatment of these adverse conditions.
 

Moreover, as the incidence of gastrointestinal disorders due to opioid use increases, there is a corresponding expansion of the patient pool actively seeking relief from opioid-induced constipation. This growing demographic of individuals experiencing gastrointestinal complications necessitates effective pharmaceutical interventions to alleviate constipation symptoms. OIC drugs, designed to specifically target constipation linked to opioid use, become essential in meeting the therapeutic needs of this expanding patient population, driving the market's growth.
 

Opioid induced constipation drugs refer to pharmaceutical agents specifically formulated to manage and alleviate constipation caused by the use of opioid medications. These drugs are designed to address the unique challenges of constipation associated with opioid use disorder, providing relief by promoting bowel movements and easing symptoms without compromising the analgesic effects of opioids.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market valuation of the opioid induced constipation drugs was reached USD 2.1 billion in 2023 and is set to expand at 4.8% CAGR up to 2032, attributed to the increasing use of opioids coupled with the rising prevalence of gastrointestinal disorders.

Opioid induced constipation drugs market from the peripherally acting mu-opioid receptor agonists (PAMORAs) segment revenue crossed USD 706.3 million in 2023 owing to their growing demand to alleviate constipation associated with opioid use, addressing a critical need in patient care.

North America opioid induced constipation drugs industry size surpassed USD 858.2 million in 2023 and is poised to expand a notable CAGR from 2024 to 2032, attributed to the presence of an advanced healthcare infrastructure in the region.

Some of the leading opioid induced constipation drug firms are Atlantis Consumer Healthcare Inc., Bausch Health Companies Inc., Bayer AG, Cumberland Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Sanofi, Shionogi & Co., Ltd., and Valinor Pharma, LLC

Opioid Induced Constipation Drugs Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 8
  • Tables & Figures: 306
  • Countries covered: 22
  • Pages: 180
 Download Free Sample